MedAvail Holdings stock (US58406B1035): restructuring, asset sale and uncertain outlook

MedAvail Holdings has radically reshaped its business after selling core assets and exiting its retail pharmacy operations. What remains of the former kiosk specialist, and what should US investors know about the latest developments?

MedAvail Holdings is undergoing a far-reaching restructuring after selling key assets of its pharmacy kiosk business and winding down related operations. The company has shifted focus toward meeting remaining obligations and exploring strategic alternatives, according to recent company filings and announcements on its investor relations site as of 03/29/2024 and 05/10/2024, as documented by MedAvail investor information as of 05/10/2024 and SEC filings as of 03/29/2024.

As of: 16.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: MedAvail Holdings
• Sector/industry: Healthcare technology / pharmacy services
• Headquarters/country: Arizona, United States
• Core markets: Retail pharmacy operators and US healthcare providers
• Key revenue drivers: Previously medication-dispensing kiosks and related pharmacy services
• Home exchange/listing venue: Previously Nasdaq Capital Market (ticker: MDVL)
• Trading currency: US dollar (USD)

MedAvail Holdings: core business model

MedAvail Holdings built its business around automated pharmacy kiosks branded as MedCenter, which allowed patients to collect prescription medicines at convenient locations while being remotely served by pharmacists. The company positioned this technology as a way to extend pharmacy coverage, especially in clinic settings and areas with limited traditional pharmacy access, according to descriptions in its Form 10-K for the year ended 12/31/2023 filed on 03/29/2024 with the US Securities and Exchange Commission and later reiterated on its corporate site, as shown in SEC filings as of 03/29/2024.

The model combined hardware, software and pharmacy licenses. MedAvail either operated kiosks through its own pharmacy entities or partnered with third-party pharmacy operators who used the MedCenter platform. This blended approach meant that its economics depended not only on equipment deployment but also on prescription volume, service fees and associated technology revenues, according to its 2023 annual report filed on 03/29/2024, as summarized by MedAvail investor materials as of 03/29/2024.

The underlying value proposition targeted clinics, health systems and retailers seeking to reduce wait times and expand medication access without building full-scale brick-and-mortar pharmacies. MedAvail emphasized the potential for extended hours, smaller footprints and integration with clinical workflows. However, the model required significant regulatory compliance, capital investment in kiosks and the ability to secure high-utilization locations, as discussed in its risk disclosures for the year ended 12/31/2023 released on 03/29/2024, according to SEC filings as of 03/29/2024.

Main revenue and product drivers for MedAvail Holdings

Historically, MedAvail’s revenues came from multiple sources: kiosk hardware sales or leases, software and technology services, and pharmacy operations linked to the MedCenter network. In the 2023 fiscal year, the company reported revenue tied predominantly to pharmacy services and technology usage rather than one-time equipment sales, reflecting its shift toward an operating and services-driven model. These details are described in the 2023 Form 10-K for the period ended 12/31/2023 filed on 03/29/2024, according to SEC filings as of 03/29/2024.

MedAvail focused on collaborating with healthcare providers who could funnel prescription volume through MedCenter kiosks. As utilization grew, recurring services revenue and margin improvement were expected to play a larger role. Yet, the company faced cost pressures from maintaining licensed pharmacies, staffing remote pharmacists and complying with diverse state regulations. These factors kept profitability under strain and contributed to continuing losses, as the company outlined for the 2023 reporting year in a filing dated 03/29/2024, referenced by MedAvail investor information as of 03/29/2024.

On the product side, MedAvail periodically updated its kiosk hardware and software to support a wider range of medications and improve reliability. The firm also explored integration with electronic health record systems and clinic workflows. Despite these enhancements, scaling the network to levels that could fully absorb fixed costs proved challenging, especially amid a competitive environment with established retail pharmacies and mail-order services, as noted in the company’s strategic discussion for the year ended 12/31/2023 published on 03/29/2024, according to SEC filings as of 03/29/2024.

Restructuring, asset sales and wind-down of operations

In 2023 and early 2024, MedAvail implemented drastic changes to its structure and operations. The company entered agreements to sell significant assets of its retail pharmacy business and related MedCenter kiosks, effectively exiting the direct operation of retail pharmacy locations and reallocating focus to winding down obligations. These strategic moves were detailed in company communications and the Form 10-K for the year ended 12/31/2023 filed on 03/29/2024, as documented by MedAvail news releases as of 03/29/2024 and SEC filings as of 03/29/2024.

The company cited persistent operating losses and limited access to additional capital as key reasons for restructuring. By selling assets and winding down certain activities, MedAvail aimed to reduce ongoing expenses and address liabilities. The 2023 annual report, released on 03/29/2024, notes that management considered a range of strategic alternatives and concluded that continuing the previous operating model would be difficult without significant new funding, according to SEC filings as of 03/29/2024.

As part of the restructuring, MedAvail also addressed its capital structure and compliance with listing standards. The company previously traded on the Nasdaq Capital Market under the MDVL ticker and received notices regarding minimum bid price and other requirements. In connection with the broader strategic review, MedAvail took steps that resulted in changes to its listing status. These developments were referenced in filings and Nasdaq communications during 2023 and early 2024, including disclosures for the year ended 12/31/2023 filed on 03/29/2024, as highlighted by MedAvail investor information as of 03/29/2024.

For shareholders, the restructuring and sale of key assets significantly altered the investment case. Instead of a growth-focused pharmacy technology company, MedAvail has increasingly become a business centered on managing remaining assets, liabilities and potential strategic transactions. The 2023 annual filing, dated 03/29/2024, explicitly discussed substantial doubt about the company’s ability to continue as a going concern without securing additional funding or completing further strategic actions, according to SEC filings as of 03/29/2024.

Financial picture and going-concern considerations

The latest full-year figures available from MedAvail describe a business under financial stress. In its Form 10-K for the year ended 12/31/2023, filed on 03/29/2024, the company reported continuing operating losses and negative cash flows from operations. While specific dollar amounts are detailed in the financial statements, management highlighted that accumulated deficits and limited capital resources raised substantial doubt about the company’s ability to remain a going concern over the next 12 months, as reported in SEC filings as of 03/29/2024.

To address liquidity needs, MedAvail pursued cost-cutting measures, asset sales and efforts to negotiate with creditors where relevant. The company also evaluated options to raise capital, though its filing noted that there could be no assurance such financing would be available on acceptable terms. These points were underscored in the 2023 annual report, which described management’s plans and the uncertainties attached to them, according to MedAvail investor materials as of 03/29/2024.

The going-concern language has important implications for equity investors. Such disclosures signal that, based on current information, the company may be unable to meet obligations or continue operations without material changes to its financial position. For MedAvail, this includes reliance on successful asset monetization, new capital or strategic transactions. The 2023 Form 10-K, filed on 03/29/2024, emphasizes that failure to achieve these objectives could result in further restructuring steps that might negatively impact the value of existing shares, as noted by SEC filings as of 03/29/2024.

Why MedAvail Holdings matters for US investors

For US investors, MedAvail’s story illustrates the challenges of scaling healthcare technology in a highly regulated and competitive pharmacy market. The company operated primarily in the United States, with its securities previously listed on a US exchange and denominated in US dollars, which made it accessible to a broad base of domestic investors. Its MedCenter kiosks were deployed in US clinics and retail locations, tying its prospects closely to US healthcare utilization and reimbursement trends, as described in the 2023 Form 10-K for the period ended 12/31/2023 filed on 03/29/2024, according to SEC filings as of 03/29/2024.

Even as the company’s operating model has shifted toward restructuring and asset management, MedAvail remains part of the broader narrative around digital health and pharmacy automation in the US. Its experience highlights the importance of capital access, regulatory navigation and partner relationships in turning promising technology into sustainable earnings. For investors tracking the segment, the developments at MedAvail provide context for evaluating other US-listed health technology names that rely on complex operational footprints, as discussed in management’s commentary for the year ended 12/31/2023 published on 03/29/2024, as summarized by MedAvail investor information as of 03/29/2024.

Conclusion

MedAvail Holdings has transitioned from an operator of pharmacy kiosks aiming for growth to a company focused on restructuring, asset sales and managing financial uncertainties. The latest available filings for the year ended 12/31/2023, published on 03/29/2024, underscore ongoing losses, liquidity pressures and substantial doubt about its ability to continue as a going concern, according to SEC filings as of 03/29/2024. For US investors, the case highlights both the innovative potential and the financial risks of healthcare technology models that depend on scale, regulation and sustained capital. Any future value creation will likely hinge on the success of MedAvail’s strategic alternatives and its ability to navigate remaining obligations in a challenging market environment.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.